Relmada Therapeutics, Inc. - Common Stock (RLMD)

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.

Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Let's have a look at the stocks with an unusual volume in today's session.

Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

These stocks have an unusual volume in today's session

Relmada Therapeutics reports interim analysis of the Phase 3 Reliance II study for REL-1017 in major depressive disorder, indicating futility in meeting efficacy goals.

RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns.

RLMD stock results show that Relmada Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

RLMD stock results show that Relmada Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.